New cream tested for painful, oozing skin condition
NCT ID NCT03972592
Summary
This study tested a topical cream containing 0.1% sirolimus to see if it could improve a rare skin condition called cutaneous microcystic lymphatic malformation (CMLM). In 55 children and adults, researchers compared the cream to an inactive version (a placebo) by applying each to a different half of the affected skin area for 12 weeks. The goal was to see if the active cream could better reduce symptoms like oozing, bleeding, and pain, and improve the skin's appearance.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULAR MALFORMATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ANGERS
Angers, France
-
BORDEAUX
Bordeaux, France
-
CAEN
Caen, France
-
DIJON
Dijon, France
-
LYON AD
Bron, France
-
LYON PED
Bron, France
-
Lariboisiere
Paris, France
-
Marseille
Marseille, France
-
Montpellier
Montpellier, France
-
NANCY
Vandœuvre-lès-Nancy, France
-
NANTES
Nantes, France
-
NECKER
Paris, France
-
NICE
Nice, France
-
QUIMPER
Quimper, France
-
RENNES
Rennes, France
-
TOULOUSE
Toulouse, France
-
TOURS
Tours, France
Conditions
Explore the condition pages connected to this study.